Company intelligence / Profile preview

Photolitec

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Photolitec is developing novel photosensitizing agents that enable both imaging and treatment of cancers. Their lead compound, PHOTOBAC, is in a Phase 1 clinical trial for glioblastoma/gliosarcoma using photodynamic therapy. The company’s technology aims to overcome limitations of current agents by improving tumor selectivity, minimizing systemic toxicity, enabling deep tissue penetration with long-wavelength activation, and providing a "see and treat" solution[2][5]. Preliminary results indicate achievement of key goals such as blood-brain barrier crossing and minimal off-target effects[2].

Therapeutic areas: Oncology
Modalities: Small moleculePhotosensitizer
Industry: Biotech

Partnerships

Licensing agreement with Roswell Park Comprehensive Cancer CenterCollaboration with University at Buffalo & University of Michigan researchers

Beyond the preview

Go deeper on Photolitec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Photolitec.